US45408X3089 - Common Stock - After market: 0.42 +0.01 (+1.3%)
NYSEARCA:IGC (2/3/2023, 7:04:00 PM)+0.01 (+3.65%)
GICS Sector | Industrials | ||
GICS Industry | Trading Companies & Distributors |
Valuation | Growth | ||
Profitability | Health | ||
Dividend |
Earnings (Last) | N/A N/A | Earnings (Next) | 02-08 2023-02-08/amc |
Ins Owners | 9.25% | Inst Owners | 9.42% |
Market Cap | 22.00M | Shares | 53.07M |
PE | N/A | Fwd PE | N/A |
Dividend Yield | N/A | Analysts | N/A |
IPO | 04-13 2006-04-13 |
Find more stocks on American Stock Exchange
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
India Globalization Capital, Inc. engages in the development and commercialization of cannabinoid based alternative therapies for indications, such as Alzheimer's disease, Parkinson's disease, and pain. The company is headquartered in Potomac, Maryland and currently employs 52 full-time employees. The company went IPO on 2006-04-13. The firm's segments include Life Sciences and Infrastructure. The Life Sciences segment operates primarily through wholly owned subsidiaries, including IGC Pharma LLC, a clinical-stage biopharmaceutical company based in Maryland. The purpose of IGC Pharma LLC is to treat Alzheimer's patients and alleviate caregiver burden. The Life Sciences segment also includes the development of over-the-counter personal care products, operated by certain of the Company's subsidiaries under various brands. The Infrastructure segment involves the execution of construction contracts and the rental of heavy construction equipment. The company has two main investigational drug assets, which are IGC-AD1 and TGR-63. Its lead therapeutic candidate, IGC-AD1 is in Phase II trials for treating agitation in dementia from Alzheimer's and TGR-63, an enzyme inhibitor to reduce neurotoxicity in Alzheimer's cell lines.
INDIA GLOBALIZATION CAPITAL
10224 Falls Road
Potomac MARYLAND 20854
P: 13019830998.0
CEO: Ram Mukunda
Employees: 52
Website: http://www.igcinc.us
Here you can normally see the latest stock twits on IGC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: